8-K Reports
AIM ImmunoTech Inc.
CIK

946644

Accepted

Dec 17, 2025, 09:30 PM

Accession

0001493152-25-028156

5.07 Submission of Matters to a Vote of Security Holders
Items (1)

Item 5.07 Submission of Matters to a Vote of Security Holders The 2025 Annual Meeting of Stockholders of AIM ImmunoTech Inc. (the “ Company”) was held on December 16, 2025 (the “ Annual Meeting”). Set forth below are the matters voted upon at the Annual Meeting, which are more fully described in the Company’s definitive proxy statement filed with the U. S. Securities and Exchange Commission on November 4, 2025, and the final voting results received from First Coast Results, Inc., the independent inspector of election for the Annual Meeting (the “ Inspector of Election”). As of the record date for the Annual Meeting, there were 2,764,188 shares of the Company’s common stock outstanding and entitled to notice of and to vote at the Annual Meeting. Of the record date shares, 1,144,383 shares, or 41.4%, were represented at the Annual Meeting either in person or by proxy, meaning the requisite quorum for the meeting of 33 1/3% was present. The final tabulation from the Inspector of Election of voting results for the election of directors and other proposals presented at the Annual Meeting was as follows: Proposal 1: Election of Directors Nominees For Withheld Broker Non-Votes ──────────────────────────────────────────────────────────────────────────── (1) Nancy K. Bryan 240,688 70,522 833,173 (2) William M. Mitchell 245,294 65,916 833,173 (3) Ted D. Kellner 280,350 30,860 833,173 (4) David I. Chemerow 273,901 37,309 833,173 (5) Thomas K. Equels 243,183 68,027 833,173 Proposal 2: Ratification, by a non-binding advisory vote, of the selection of BDO USA, P. C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 For: Against: Abstain: ───────────────────────────────────────── 1,104,780 29,754 9,849 Based on the final voting results reported by the Inspector of Election, Proposal 2 was approved. Proposal 3: Approval, by a non-binding advisory vote, of the compensation of the Company’s named executive officers For: Against: Abstain: Broker Non Votes: ────────────────────────────────────────────────────────────── 193,668 115,337 2,505 833,173 Proposal 3 received a majority of the votes cast (excluding broker non-votes). Broker non-votes consist of shares held by brokerage firms, banks, trustees or other nominees on behalf of a beneficial owner which were not voted either for or against Proposal 3 because the beneficial owner did not provide voting instructions and the brokerage firm, bank, trustee or other nominee lacked the discretionary power to vote such shares. After accounting for these broker non-votes, Proposal 3 did not receive the affirmative vote of the holders of a majority in voting power represented by proxy or present at the Annual Meeting and entitled to vote on the matter, therefore could not be approved. The Company notes that a majority of the votes cast approved, on an advisory basis, the compensation of the Company’s named executives. Proposal 4: Approval, by a non-binding advisory vote, of the frequency of executive compensation votes 1 Year: 2 Years: 3 Years: Abstain: Broker Non Votes: ──────────────────────────────────────────────────────────────────────────── 284,856 3,920 15,484 6,950 833,173 The choice to hold a non-binding advisory vote on executive compensation annually received the highest number of the votes cast, and consistent with the Board’s recommendation, the Board has determined to hold a non-binding advisory vote regarding executive compensation every year until the next required non-binding advisory vote on the frequency of holding votes regarding executive compensation. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM Date: By: /s/ Thomas

AIM ImmunoTech Inc. — 8-K Filing | LevelFields AI